{"id":"romosozumab-hcp-administration-with-pfs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Back pain"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to sclerostin, romosozumab increases bone formation and decreases bone resorption, leading to increased bone density and reduced risk of fractures. This mechanism is thought to be beneficial in the treatment of osteoporosis and other bone-related disorders.","oneSentence":"Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:44.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoporosis in postmenopausal women at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT03432533","phase":"PHASE3","title":"A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-02-06","conditions":"Post-Menopausal Osteoporosis","enrollment":283}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Evenity","AMG785"],"phase":"phase_3","status":"active","brandName":"romosozumab HCP administration with PFS","genericName":"romosozumab HCP administration with PFS","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation. Used for Treatment of osteoporosis in postmenopausal women at high risk of fracture.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}